Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib for the Treatment of Palmoplantar Pustulosis
NCT05710185Phase 4Terminated
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of deucravacitinib in palmoplantar pustulosis (PPP), sponsored by Brigham and Women's Hospital. Started Jul 2023; status: terminated.
02
Drugs
deucravacitinib
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT05710185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05710185.